Allan Jacobson - PTC Therapeutics Chairman
| PTCT Stock | USD 32.14 3.57 12.50% |
Chairman
Dr. Allan S. Jacobson, Ph.D. is Independent Director of PTC Therapeutics Inc., since 1998. Dr. Jacobson has served as a member of our Board since our inception in 1998, and previously served as Chairman of our Board from 1998 to 2004. Since 2000, Dr. Jacobson has served as Chairman of our scientific advisory board. Since 1994, Dr. Jacobson was the Chairman of the Department of Microbiology and Physiological Systems at the University of Massachusetts Medical School. In 1982, Dr. Jacobson cofounded Applied bioTechnology, Inc., a biotechnology company, and served as its chairman until its sale in 1991. From 1987 to 1990, Dr. Jacobson served as special limited partner at Euclid Partners, a VC firm since 1998.
| Age | 78 |
| Tenure | 26 years |
| Professional Marks | Ph.D |
| Address | 100 Corporate Court, South Plainfield, NJ, United States, 07080 |
| Phone | 908 222 7000 |
| Web | https://www.ptcbio.com |
PTC Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1029) % which means that it has lost $0.1029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (77.4012) %, meaning that it created substantial loss on money invested by shareholders. PTC Therapeutics' management efficiency ratios could be used to measure how well PTC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.80 in 2024, whereas Return On Tangible Assets are likely to drop (0.46) in 2024. At this time, PTC Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2.2 B in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1 B in 2024.Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| Keith Gollust | Madrigal Pharmaceuticals | 72 | |
| Daniel Lynch | Blueprint Medicines Corp | 60 | |
| Gary Jacob | Hepion Pharmaceuticals | 70 | |
| William Goolsbee | Sarepta Therapeutics | 60 | |
| Iain Dukes | Iovance Biotherapeutics | 59 | |
Management Performance
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.1 |
PTC Therapeutics Leadership Team
Elected by the shareholders, the PTC Therapeutics' board of directors comprises two types of representatives: PTC Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PTC. The board's role is to monitor PTC Therapeutics' management team and ensure that shareholders' interests are well served. PTC Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PTC Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Schmertzler, Chairman of the Board | ||
| Emma Reeve, Independent Director | ||
| Stephanie Okey, Independent Director | ||
| Ronald Renaud, Director | ||
| Emily Hill, Principal Financial Officer, Treasurer | ||
| FACS MD, CEO Director | ||
| Neil Almstead, Executive VP of Research, Pharmaceutical Operations and Technology | ||
| Marcio Souza, COO | ||
| Dawn Svoronos, Director | ||
| Hege SollieZetlmayer, Senior Resources | ||
| Geoffrey McDonough, Independent Director | ||
| Adam Koppel, Independent Director | ||
| Jerome Zeldis, Independent Director | ||
| Christine Utter, Principal Financial Officer, Principal Accounting Officer, Treasurer | ||
| Glenn Steele, Director | ||
| Ellen Welch, Chief Officer | ||
| David Southwell, Independent Director | ||
| FACS FACS, Chief Officer | ||
| Mark Boulding, Chief Legal Officer and Executive VP | ||
| Tuyen Ong, Chief Medical Officer | ||
| Stuart Peltz, Co-Founder, CEO and Executive Director | ||
| Alex Kane, Investor Officer | ||
| Shane Kovacs, CFO, Head of Corporate Devel. and Executive VP | ||
| Eric Pauwels, Chief Officer | ||
| Mark Rothera, Chief Commercial Officer | ||
| Robert Spiegel, Chief Medical Officer | ||
| Pierre MS, Chief Officer | ||
| Jane Baj, Vice Communications | ||
| Allan Jacobson, Co-Founder, Chairman of Scientific Advisory Board, Director and Member of Nominating and Corporate Governance Committee |
PTC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PTC Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.62) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 3.57 B | ||||
| Shares Outstanding | 76.61 M | ||||
| Shares Owned By Insiders | 2.77 % | ||||
| Shares Owned By Institutions | 97.23 % | ||||
| Number Of Shares Shorted | 10.2 M | ||||
| Price To Earning | (5.67) X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PTC Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for PTC Stock analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 12.281 | Quarterly Revenue Growth (0.05) | Return On Assets (0.10) | Return On Equity (77.40) |
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.